Skip to main content
Clinical Trials/CTRI/2021/02/031090
CTRI/2021/02/031090
Not yet recruiting
Phase 2

A comparative clinical study of NÄ?gakesara CÅ«rnÌ£a and KutakÄ« CÅ«rnÌ£a in the management of AsrÌ£gdara with special reference to Dysfunctional Uterine Bleeding.

ational Institute of Ayurveda0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
ational Institute of Ayurveda
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients ready to participate in the clinical trial.
  • 2\) Patients diagnosed as dysfunctional uterine bleeding.
  • 3\) Excessive menstrual bleeding (amount \>80 ml) or Prolonged menstrual bleeding ( \>7 days) with or without heavy flow or Frequent menstrual cycle (interval \< 21 days)
  • 4\) Patients presenting with inter\-menstrual bleeding with or without heavy flow for 2 consecutive cycles.

Exclusion Criteria

  • 1\) Patients with chronic systemic illness (Congestive cardiac failure, Hypertension, cirrhosis of liver, Tuberculosis endometritis, severe anaemia, chronic renal disease, Insulin dependent diabetes mellitus etc.).
  • 2\) Patients using Intrauterine contraceptive device or oral contraceptive pills (Iatrogenic).
  • 3\) Patients with uterine and pelvic pathology (Fibroid size \>2 cm, endometriosis, adenomyosis, polyp, high grade cervical erosion, endometrial thickness \>20 mm etc.).
  • 4\) Congenital malformations of uterus(Septate uterus, double uterus).
  • 5\) Benign and malignant growth.
  • 6\) Thyroid dysfunction (endocrinal disorders).
  • 7\) Patients having bleeding due to abortion, ectopic pregnancy, during puerperium.
  • 8\) Patients taking Anti\-coagulation therapy and having haematological disorders (Leukemia, Thrombocytopenic Purpura).
  • 9\) Postmenopausal bleeding.
  • 10\) Sexually transmitted infections/Genital tract infections.

Outcomes

Primary Outcomes

Not specified

Similar Trials